Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW MICHAEL LERMAN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Epilepsy

NPI
1407173974
CMS profile
1326930
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$64,854.96

304 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 7; records 51–100 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW MICHAEL LERMAN

NPI 1407173974 · CMS profile ID 1326930

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Epilepsy

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 7; records 51–100 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407173974?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW MICHAEL LERMAN, NPI 1407173974, CMS profile ID 1326930. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407173974?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ANDREW MICHAEL LERMAN, NPI 1407173974, CMS profile ID 1326930. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407173974?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ANDREW MICHAEL LERMAN, NPI 1407173974, CMS profile ID 1326930, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 304 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1407173974?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

304 matching records · $64,854.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 304 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 304.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ARGENX US, INC. $23.0110/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142117703 CMS
ARGENX US, INC. $124.9910/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142116587 CMS
JAZZ PHARMACEUTICALS INC. $13.5410/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150213146 CMS
ABBVIE INC. $18.3210/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104163358 CMS
PFIZER INC. $20.5110/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131987505 CMS
Neurelis, Inc. $125.0010/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145646491 CMS
Takeda Pharmaceuticals U.S.A., Inc. $27.8210/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137618212 CMS
Lundbeck LLC $20.6510/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145939028 CMS
Neurocrine Biosciences, Inc. $27.6510/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150832202 CMS
Neurocrine Biosciences, Inc. $2,800.0010/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150856932 CMS
ABBVIE INC. $19.5210/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104163356 CMS
Amneal Pharmaceuticals LLC $22.5310/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139193024 CMS
ARGENX US, INC. $1,600.0010/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142113915 CMS
ARGENX US, INC. $1,600.0010/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142115733 CMS
Lilly USA, LLC $28.9410/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136040147 CMS
ABBVIE INC. $21.6510/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104163354 CMS
ARGENX US, INC. $9.9709/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142123175 CMS
MDD US Operations, LLC $826.9309/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147759193 CMS
MDD US Operations, LLC $2,310.0009/27/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147759195 CMS
MDD US Operations, LLC $32.4009/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147759199 CMS
MDD US Operations, LLC $45.9009/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147759201 CMS
MDD US Operations, LLC $115.5009/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147759203 CMS
MDD US Operations, LLC $132.1009/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147759205 CMS
JAZZ PHARMACEUTICALS INC. $34.9309/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150213164 CMS
UCB, Inc. $13.4109/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143127291 CMS
UCB, Inc. $64.0509/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143127296 CMS
PFIZER INC. $18.0109/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131948142 CMS
ABBVIE INC. $20.5209/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104163352 CMS
Boston Scientific Corporation $27.6709/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092423077 CMS
UCB, Inc. $840.0009/17/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143127287 CMS
ARGENX US, INC. $23.9809/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142111625 CMS
ABBVIE INC. $28.4809/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104163348 CMS
ABBVIE INC. $75.0009/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104163350 CMS
Otsuka America Pharmaceutical, Inc. $25.0809/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118929830 CMS
SCILEX PHARMACEUTICALS INC. $22.6109/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136270224 CMS
Abbott Laboratories $5.3509/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125048453 CMS
Amneal Pharmaceuticals LLC $8.1609/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139193022 CMS
Neurelis, Inc. $19.2209/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145646489 CMS
Lilly USA, LLC $117.1209/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136040149 CMS
PFIZER INC. $23.9208/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131884249 CMS
Teva Pharmaceuticals USA, Inc. $25.1308/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151478762 CMS
ABBVIE INC. $10.5508/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104163346 CMS
SCILEX PHARMACEUTICALS INC. $2,000.0008/28/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136267455 CMS
ABBVIE INC. $31.6508/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104163344 CMS
Amneal Pharmaceuticals LLC $8.2008/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139193020 CMS
Neurocrine Biosciences, Inc. $105.4008/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150811787 CMS
Neurocrine Biosciences, Inc. $2,800.0008/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150856896 CMS
Abbott Laboratories $22.9508/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125048451 CMS
ARGENX US, INC. $24.4808/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142110251 CMS
Neurocrine Biosciences, Inc. $23.1308/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150846119 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $16,221.82 163
PY2020 $5,741.26 100
PY2021 $13,187.91 242
PY2022 $28,694.51 237
PY2023 $68,910.39 270
PY2024 $64,854.96 304
PY2025 $51,700.19 246

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,197,791.18 29
PY2024 Recipient $110,925.00 2
PY2024 Principal investigator $1,637,807.41 14
PY2023 Recipient $4,889.58 1
PY2023 Principal investigator $900,023.23 16
PY2022 Recipient $24,024.00 2
PY2022 Principal investigator $433,543.60 9
PY2021 Recipient $169.80 1
PY2021 Principal investigator $8,992.21 2
PY2020 Recipient $7,997.00 1
PY2020 Principal investigator $35,926.17 3
PY2019 Recipient $7,910.00 1
PY2019 Principal investigator $1,918.59 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,731.00 12/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223289754
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,731.00 12/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223289756
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,731.00 12/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223289758
Principal investigator 1 Genentech, Inc. $3,850.00 12/11/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211682520
Principal investigator 1 Genentech, Inc. $9,380.00 11/20/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211682518
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,960.75 11/20/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223288639
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,731.00 10/16/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223287047
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $252.10 10/13/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223286719
Principal investigator 1 ARGENX US, INC. $63,893.20 10/10/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237161469
Principal investigator 1 Novartis Pharmaceuticals Corporation $281,035.88 10/08/2025 Non-covered Recipient Entity
GABLES NEUROLOGY
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190308798
Principal investigator 1 Genentech, Inc. $10,000.00 09/18/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211682516
Principal investigator 1 ARGENX US, INC. $10,625.00 09/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis No dispute reported 06/30/2026 1237161457
Principal investigator 1 ARGENX US, INC. $2,600.00 09/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis No dispute reported 06/30/2026 1237161462
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,664.75 09/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223285478
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,317.00 09/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223285480
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,362.01 09/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223285482
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,731.00 09/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223285492
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,731.00 09/17/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223285520
Principal investigator 1 Eli Lilly and Company $17,860.00 08/04/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST-P-TAU217 RESULT: A RANDOMIZED CLINICAL UTILITY STUDY No dispute reported 06/30/2026 1187892932
Principal investigator 1 Eli Lilly and Company $15,495.00 03/11/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187891414
Principal investigator 1 ARGENX US, INC. $15,000.00 03/05/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237161465
Principal investigator 1 Eli Lilly and Company $290,748.00 02/25/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187892922
Principal investigator 1 Eli Lilly and Company $17,866.00 02/18/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187892678
Principal investigator 1 Eli Lilly and Company $348,473.00 02/10/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187892734
Principal investigator 1 Eli Lilly and Company $6,130.59 01/27/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187892738
Principal investigator 1 Eli Lilly and Company $9,918.93 01/09/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187893446
Principal investigator 1 Eli Lilly and Company $869.23 01/09/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187893450
Principal investigator 1 UCB SA $59,814.00 01/07/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246657990
Principal investigator 1 Eli Lilly and Company $6,289.74 01/02/2025 Non-covered Recipient Entity
VISIONARY INVESTIGATORS NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187892670